CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report
Background: Pancreatic ductal adenocarcinoma (PDAC) is aggressive, with more than 80% present with metastatic disease, and an overall survival of less than a year with systemic chemotherapy treatment. Cytoreductive surgery (CRS) and intraperitoneal chemotherapy are two treatment modalities being exp...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Surgical Society of North Greece
2023
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/107180/ http://psasir.upm.edu.my/id/eprint/107180/1/CRS%20and%20HIPEC%20for%20pancreatic%20ductal%20adenocarcinoma%20with%20peritoneal%20metastases.pdf |
| _version_ | 1848864864934559744 |
|---|---|
| author | Amin-Tai, Hizami Adznan, Muhammad Ash-Shafhawi Canda, Aras Emre Yılmaz, Hüseyin Cahit Kılıç, Murat Terzi, Mustafa Cem |
| author_facet | Amin-Tai, Hizami Adznan, Muhammad Ash-Shafhawi Canda, Aras Emre Yılmaz, Hüseyin Cahit Kılıç, Murat Terzi, Mustafa Cem |
| author_sort | Amin-Tai, Hizami |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Background: Pancreatic ductal adenocarcinoma (PDAC) is aggressive, with more than 80% present with metastatic disease, and an overall survival of less than a year with systemic chemotherapy treatment. Cytoreductive surgery (CRS) and intraperitoneal chemotherapy are two treatment modalities being explored to improve the survival rates of these patients. Case presentation: A 45-year-old man presented with epigastric pain, mass, and weight loss. Investigations revealed a pancreatic tumour with liver and extensive peritoneal metastases. After 18 cycles of chemotherapy, there was significant disease regression which allowed CRS and HIPEC to be performed. HIPEC, PIPAC, and repeated intraperitoneal liquid chemotherapy have been shown to be safe. Longer survival and reduced disease related complications are among the advantages seen in published data. Conclusion: Complete cytoreduction and HIPEC, repeated cycles of either intraperitoneal chemotherapy or PIPAC, are associated with longer survival and reasonable adverse effects. Patients diagnosed with PDAC and peritoneal metastases should be considered for these treatment strategies. |
| first_indexed | 2025-11-15T13:55:36Z |
| format | Article |
| id | upm-107180 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T13:55:36Z |
| publishDate | 2023 |
| publisher | Surgical Society of North Greece |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-1071802024-10-17T03:44:45Z http://psasir.upm.edu.my/id/eprint/107180/ CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report Amin-Tai, Hizami Adznan, Muhammad Ash-Shafhawi Canda, Aras Emre Yılmaz, Hüseyin Cahit Kılıç, Murat Terzi, Mustafa Cem Background: Pancreatic ductal adenocarcinoma (PDAC) is aggressive, with more than 80% present with metastatic disease, and an overall survival of less than a year with systemic chemotherapy treatment. Cytoreductive surgery (CRS) and intraperitoneal chemotherapy are two treatment modalities being explored to improve the survival rates of these patients. Case presentation: A 45-year-old man presented with epigastric pain, mass, and weight loss. Investigations revealed a pancreatic tumour with liver and extensive peritoneal metastases. After 18 cycles of chemotherapy, there was significant disease regression which allowed CRS and HIPEC to be performed. HIPEC, PIPAC, and repeated intraperitoneal liquid chemotherapy have been shown to be safe. Longer survival and reduced disease related complications are among the advantages seen in published data. Conclusion: Complete cytoreduction and HIPEC, repeated cycles of either intraperitoneal chemotherapy or PIPAC, are associated with longer survival and reasonable adverse effects. Patients diagnosed with PDAC and peritoneal metastases should be considered for these treatment strategies. Surgical Society of North Greece 2023-10 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/107180/1/CRS%20and%20HIPEC%20for%20pancreatic%20ductal%20adenocarcinoma%20with%20peritoneal%20metastases.pdf Amin-Tai, Hizami and Adznan, Muhammad Ash-Shafhawi and Canda, Aras Emre and Yılmaz, Hüseyin Cahit and Kılıç, Murat and Terzi, Mustafa Cem (2023) CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report. Surgical Chronicles, 28 (4). pp. 460-463. ISSN 1108-5002 https://www.surgchronicles.gr/components/com_journals/journals/2023/4/22.pdf |
| spellingShingle | Amin-Tai, Hizami Adznan, Muhammad Ash-Shafhawi Canda, Aras Emre Yılmaz, Hüseyin Cahit Kılıç, Murat Terzi, Mustafa Cem CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report |
| title | CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report |
| title_full | CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report |
| title_fullStr | CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report |
| title_full_unstemmed | CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report |
| title_short | CRS and HIPEC for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report |
| title_sort | crs and hipec for pancreatic ductal adenocarcinoma with peritoneal metastases: a case report |
| url | http://psasir.upm.edu.my/id/eprint/107180/ http://psasir.upm.edu.my/id/eprint/107180/ http://psasir.upm.edu.my/id/eprint/107180/1/CRS%20and%20HIPEC%20for%20pancreatic%20ductal%20adenocarcinoma%20with%20peritoneal%20metastases.pdf |